Orthofix is spine and extremities and one of the world's leading orthopedic suppliers.
Orthofix Medical is a focused spine and extremities company generating approximately $700 million in annual revenue, formed through the 2023 merger of Orthofix International and SeaSpine Holdings. The company's spine portfolio encompasses biologics, interbody fusion devices, and bone growth stimulation technology — with the Trinity Elite demineralized bone matrix platform as a key commercial asset. Orthofix's extremities portfolio covers fixation systems for long bone fractures and deformity correction. The company occupies a focused mid-market position between the large diversified OEMs and smaller specialty companies.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Acquisitions and divestitures
• Marketing tactics
• Financial results
• Strengths and weaknesses
• Strategic directions
Table of Contents
1. Executive Summary
2. Company Overview and Business Model
3. Strategic Directions
4. Financial Results
5. SWOT Analysis
6. Technological Know-How and Key Products
7. Acquisitions and Divestitures
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Orthofix — Key Financial Metrics 2023-2025
Table 2. Orthofix — Revenue by Segment 2023-2025
Table 3. Orthofix — Revenue by Geography 2023-2025
Table 4. Orthofix — SWOT Analysis
Table 5. Orthofix — Key Products and Platforms 2025
Table 6. Orthofix — M&A Activity 2020-2025
Table 7. Orthofix — Key Management 2025
Table 8. Orthofix — Strategic Priorities 2025-2030
